South Korea · Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 691.59 billion. The enterprise value is 718.83 billion.
| Market Cap | 691.59B |
| Enterprise Value | 718.83B |
Important Dates
The last earnings date was Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 13.72 million shares outstanding. The number of shares has increased by 0.90% in one year.
| Current Share Class | 13.72M |
| Shares Outstanding | 13.72M |
| Shares Change (YoY) | +0.90% |
| Shares Change (QoQ) | +2.76% |
| Owned by Insiders (%) | 25.77% |
| Owned by Institutions (%) | 6.85% |
| Float | 8.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.90 |
| PB Ratio | 9.75 |
| P/TBV Ratio | 9.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -26.19 |
| EV / Sales | 7.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.81 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.16 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.67 |
| Interest Coverage | -13.85 |
Financial Efficiency
Return on equity (ROE) is -41.69% and return on invested capital (ROIC) is -30.27%.
| Return on Equity (ROE) | -41.69% |
| Return on Assets (ROA) | -12.16% |
| Return on Invested Capital (ROIC) | -30.27% |
| Return on Capital Employed (ROCE) | -31.49% |
| Weighted Average Cost of Capital (WACC) | 16.16% |
| Revenue Per Employee | 361.62M |
| Profits Per Employee | -99.08M |
| Employee Count | 277 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.39 |
Taxes
In the past 12 months, HansBiomed has paid 1.35 billion in taxes.
| Income Tax | 1.35B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +519.93% in the last 52 weeks. The beta is 2.31, so HansBiomed's price volatility has been higher than the market average.
| Beta (5Y) | 2.31 |
| 52-Week Price Change | +519.93% |
| 50-Day Moving Average | 33,840.00 |
| 200-Day Moving Average | 19,970.40 |
| Relative Strength Index (RSI) | 68.73 |
| Average Volume (20 Days) | 388,175 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 100.17 billion and -27.44 billion in losses. Loss per share was -2,098.06.
| Revenue | 100.17B |
| Gross Profit | 58.71B |
| Operating Income | -25.31B |
| Pretax Income | -26.84B |
| Net Income | -27.44B |
| EBITDA | -20.36B |
| EBIT | -25.31B |
| Loss Per Share | -2,098.06 |
Balance Sheet
The company has 15.92 billion in cash and 43.17 billion in debt, with a net cash position of -27.26 billion or -1,986.26 per share.
| Cash & Cash Equivalents | 15.92B |
| Total Debt | 43.17B |
| Net Cash | -27.26B |
| Net Cash Per Share | -1,986.26 |
| Equity (Book Value) | 70.90B |
| Book Value Per Share | 5,313.95 |
| Working Capital | 9.82B |
Cash Flow
In the last 12 months, operating cash flow was -23.49 billion and capital expenditures -2.35 billion, giving a free cash flow of -25.84 billion.
| Operating Cash Flow | -23.49B |
| Capital Expenditures | -2.35B |
| Free Cash Flow | -25.84B |
| FCF Per Share | -1,883.35 |
Margins
Gross margin is 58.62%, with operating and profit margins of -25.27% and -27.40%.
| Gross Margin | 58.62% |
| Operating Margin | -25.27% |
| Pretax Margin | -26.79% |
| Profit Margin | -27.40% |
| EBITDA Margin | -20.32% |
| EBIT Margin | -25.27% |
| FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.90% |
| Shareholder Yield | -0.90% |
| Earnings Yield | -3.97% |
| FCF Yield | -3.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 1.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.28 |
| Piotroski F-Score | 3 |